Nebenwirkungen · Kentera (previously Oxybutynin Nicobrand)
Kentera 3.9 mg / 24 hours transdermal patch · Abschnitt 4.8 · PDF-Seite 4
HOS-112670 · Präparat HOS-093719
Tabulated list of adverse reactions Adverse reactions from phase 3 and 4 clinical studies are listed below by system organ class and frequency grouping. Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Post- marketing adverse reactions not seen in clinical trials are also included.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-08T02:00:00Z · SHA-256 f16314d201d86c4de73d4a8a846ed94a7bcbbf05b4bc16677f6a496640258172 · Passage 07eb1fbfcbe8f489d9aaf15d2a22c13f96be00126e8d2c33339e527f82426168 · Zeichen 326–820 im Abschnitt